GlykoGen

GlykoGen Limited was formed and registered in Scotland, in October 2016 by its founder Dr Kimberley Mackenzie. GlykoGen’s product pipeline of engineered monoclonal antibodies are produced using their novel immunisation process and antibody platform. Delivering to both the research and therapeutics markets, antibodies against glycans which had previously been difficult to generate. These high-affinity class-switched (IgG) antibodies target carbohydrates found on the surface of cancerous cells.

GlykoGen will create, screen, modify and demonstrate the action of the antibodies against glycans found on cells linked to various cancers of the breast, pancreas, colon, lung, ovary and kidney. GlykoGen’s product pipeline includes unique rabbit antibodies which are not currently commercially available. Suitable therapeutic candidates will be licenced to pharmaceutical companies along with the accompanying data package.